. 2023 May;24(5):443-456.

doi: 10.1016/S1470-2045(23)00148-1.

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard¹, Laura Murphy², Noel W Clarke³, Ashwin Sachdeva³, Craig Jones³, Alex Hoyle³, William Cross⁴, Robert J Jones⁵, Christopher C Parker⁶, Silke Gillessen⁷, Adrian Cook², Chris Brawley², Clare Gilson², Hannah Rush⁸, Hoda Abdel-Aty⁶, Claire L Amos², Claire Murphy², Simon Chowdhury⁹, Zafar Malik¹⁰, J Martin Russell¹¹, Nazia Parkar², Cheryl Pugh², Carlos Diaz-Montana², Carmel Pezaro¹², Warren Grant¹³, Helen Saxby¹⁴, Ian Pedley¹⁵, Joe M O'Sullivan¹⁶, Alison Birtle¹⁷, Joanna Gale¹⁸, Narayanan Srihari¹⁹, Carys Thomas²⁰, Jacob Tanguay²¹, John Wagstaff¹², Prantik Das²², Emma Gray²³, Mymoona Alzouebi²⁴, Omi Parikh²⁵, Angus Robinson²⁶, Amir H Montazeri¹⁰, James Wylie³, Anjali Zarkar²⁷, Richard Cathomas²⁸, Michael D Brown³, Yatin Jain³, David P Dearnaley⁶, Malcolm D Mason²⁹, Duncan Gilbert², Ruth E Langley², Robin Millman², David Matheson³⁰, Matthew R Sydes², Louise C Brown², Mahesh K B Parmar², Nicholas D James⁶; STAMPEDE investigators

Collaborators, Affiliations

Collaborators

STAMPEDE investigators:
Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Warren Grant, Katherine Hyde, Ami Sabharwal, Uschi Hofmann, Robert Dealey, Neil McPhail, Robert Brierly, Simon Brown, Lisa Capaldi, Norma Sidek, Peter Whelan, Thiagarajan Sreenivasan, Peter Robson, Alison Falconer, Sarah Rudman, Sindu Vivekanandan, Vinod Mullessey, Sarah Needleman, Maria Vilarino-Varela, Vincent Khoo, Karen Tipples, Mehran Afshar, Alison Falconer, Patryk Brulinski, Vijay Sangar, Clive Peedell, Ashraf Azzabi, Peter Hoskin, Viwod Mullassery, Santhanam Sundar, Yakhub Khan, Ruth Conroy, Andrew Protheroe, Judith Carser, Paul Rogers, Lisa Capaldi, Kathryn Tarver, Stephanie Gibbs, Mohammad Muneeb Khan, Mohan Hingorani, Ashraf Azzabi, Simon Crabb, Manal Alameddine, Neeraj Bhalla, Caroline Manetta, Robert Hughes, John Logue, Darren Leaning, Salil Vengalil, Ashraf Azzabi, Daniel Ford, Georgina Walker, Ahmed Shaheen, Omar Khan, Andrew Chan, Imtiaz Ahmed, Serena Hilman, Fiona Douglas, Anil Kumar, Anna Tran, Sangeeta Paisey, Ian Sayers, Lisa Capaldi, Ashok Nikapota, David Bloomfield, Tim Porter, Joji Joseph, Cyrill Rentsch, Ricardo Pereira Mestre, Enrico Roggero, Jörg Beyer, Markus Borner, Raeto Strebel, Dominik Berthold, Daniel Engeler, Hubert John, Razvan Popescu, Donat Durr

Affiliations

¹ Cancer Institute, University College London, London, UK; University College London Hospitals, London, UK. Electronic address: g.attard@ucl.ac.uk.
² Medical Research Council Clinical Trials Unit, University College London, London, UK.
³ Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
⁴ St James's University Hospital, Leeds, UK.
⁵ Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
⁶ Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
⁷ Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; CH and Universita della Svizzera Italiana, Lugano, Switzerland.
⁸ Medical Research Council Clinical Trials Unit, University College London, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁹ Guy's and St Thomas' NHS Foundation Trust, London, UK.
¹⁰ Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK.
¹¹ Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
¹² Singleton Hospital, Swansea, UK.
¹³ Gloucestershire Oncology Centre, Cheltenham, UK.
¹⁴ Torbay and South Devon NHS Foundation Trust, Torbay, UK.
¹⁵ Northern Centre for Cancer Care, Newcastle upon Tyne, UK.
¹⁶ Queen's University Belfast, Belfast, UK.
¹⁷ Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK.
¹⁸ Queen Alexandra Hospital, Portsmouth, UK.
¹⁹ Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK.
²⁰ Kent Oncology Centre, Maidstone, UK.
²¹ Velindre Cancer Centre, Cardiff, UK.
²² Royal Derby Hospital, Derby, UK.
²³ Yeovil District Hospital NHS Foundation Trust, Yeovil, UK.
²⁴ Weston Park Hospital, Sheffield, UK.
²⁵ East Lancashire Hospitals NHS Trust, Preston, UK.
²⁶ Royal Sussex County Hospital, Brighton, UK.
²⁷ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
²⁸ Division of Oncology and Hematology, Cantonal Hospital Graubünden, Chur, Switzerland; Swiss Group for Clinical Cancer Research, Bern, Switzerland.
²⁹ Cardiff University, Cardiff, UK.
³⁰ Faculty of Education Health and Wellbeing, University of Wolverhampton, Walsall, UK.

PMID: 37142371
PMCID: PMC7616864
DOI: 10.1016/S1470-2045(23)00148-1

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard et al. Lancet Oncol. 2023 May.

. 2023 May;24(5):443-456.

doi: 10.1016/S1470-2045(23)00148-1.

Authors

Collaborators

STAMPEDE investigators:
Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Warren Grant, Katherine Hyde, Ami Sabharwal, Uschi Hofmann, Robert Dealey, Neil McPhail, Robert Brierly, Simon Brown, Lisa Capaldi, Norma Sidek, Peter Whelan, Thiagarajan Sreenivasan, Peter Robson, Alison Falconer, Sarah Rudman, Sindu Vivekanandan, Vinod Mullessey, Sarah Needleman, Maria Vilarino-Varela, Vincent Khoo, Karen Tipples, Mehran Afshar, Alison Falconer, Patryk Brulinski, Vijay Sangar, Clive Peedell, Ashraf Azzabi, Peter Hoskin, Viwod Mullassery, Santhanam Sundar, Yakhub Khan, Ruth Conroy, Andrew Protheroe, Judith Carser, Paul Rogers, Lisa Capaldi, Kathryn Tarver, Stephanie Gibbs, Mohammad Muneeb Khan, Mohan Hingorani, Ashraf Azzabi, Simon Crabb, Manal Alameddine, Neeraj Bhalla, Caroline Manetta, Robert Hughes, John Logue, Darren Leaning, Salil Vengalil, Ashraf Azzabi, Daniel Ford, Georgina Walker, Ahmed Shaheen, Omar Khan, Andrew Chan, Imtiaz Ahmed, Serena Hilman, Fiona Douglas, Anil Kumar, Anna Tran, Sangeeta Paisey, Ian Sayers, Lisa Capaldi, Ashok Nikapota, David Bloomfield, Tim Porter, Joji Joseph, Cyrill Rentsch, Ricardo Pereira Mestre, Enrico Roggero, Jörg Beyer, Markus Borner, Raeto Strebel, Dominik Berthold, Daniel Engeler, Hubert John, Razvan Popescu, Donat Durr

Affiliations

¹ Cancer Institute, University College London, London, UK; University College London Hospitals, London, UK. Electronic address: g.attard@ucl.ac.uk.
² Medical Research Council Clinical Trials Unit, University College London, London, UK.
³ Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
⁴ St James's University Hospital, Leeds, UK.
⁵ Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
⁶ Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
⁷ Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; CH and Universita della Svizzera Italiana, Lugano, Switzerland.
⁸ Medical Research Council Clinical Trials Unit, University College London, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁹ Guy's and St Thomas' NHS Foundation Trust, London, UK.
¹⁰ Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK.
¹¹ Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
¹² Singleton Hospital, Swansea, UK.
¹³ Gloucestershire Oncology Centre, Cheltenham, UK.
¹⁴ Torbay and South Devon NHS Foundation Trust, Torbay, UK.
¹⁵ Northern Centre for Cancer Care, Newcastle upon Tyne, UK.
¹⁶ Queen's University Belfast, Belfast, UK.
¹⁷ Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK.
¹⁸ Queen Alexandra Hospital, Portsmouth, UK.
¹⁹ Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK.
²⁰ Kent Oncology Centre, Maidstone, UK.
²¹ Velindre Cancer Centre, Cardiff, UK.
²² Royal Derby Hospital, Derby, UK.
²³ Yeovil District Hospital NHS Foundation Trust, Yeovil, UK.
²⁴ Weston Park Hospital, Sheffield, UK.
²⁵ East Lancashire Hospitals NHS Trust, Preston, UK.
²⁶ Royal Sussex County Hospital, Brighton, UK.
²⁷ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
²⁸ Division of Oncology and Hematology, Cantonal Hospital Graubünden, Chur, Switzerland; Swiss Group for Clinical Cancer Research, Bern, Switzerland.
²⁹ Cardiff University, Cardiff, UK.
³⁰ Faculty of Education Health and Wellbeing, University of Wolverhampton, Walsall, UK.

PMID: 37142371
PMCID: PMC7616864
DOI: 10.1016/S1470-2045(23)00148-1

Abstract

Background: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-term outcomes and test whether combining enzalutamide with abiraterone and androgen deprivation therapy improves survival.

Methods: We analysed two open-label, randomised, controlled, phase 3 trials of the STAMPEDE platform protocol, with no overlapping controls, conducted at 117 sites in the UK and Switzerland. Eligible patients (no age restriction) had metastatic, histologically-confirmed prostate adenocarcinoma; a WHO performance status of 0-2; and adequate haematological, renal, and liver function. Patients were randomly assigned (1:1) using a computerised algorithm and a minimisation technique to either standard of care (androgen deprivation therapy; docetaxel 75 mg/m² intravenously for six cycles with prednisolone 10 mg orally once per day allowed from Dec 17, 2015) or standard of care plus abiraterone acetate 1000 mg and prednisolone 5 mg (in the abiraterone trial) orally or abiraterone acetate and prednisolone plus enzalutamide 160 mg orally once a day (in the abiraterone and enzalutamide trial). Patients were stratified by centre, age, WHO performance status, type of androgen deprivation therapy, use of aspirin or non-steroidal anti-inflammatory drugs, pelvic nodal status, planned radiotherapy, and planned docetaxel use. The primary outcome was overall survival assessed in the intention-to-treat population. Safety was assessed in all patients who started treatment. A fixed-effects meta-analysis of individual patient data was used to compare differences in survival between the two trials. STAMPEDE is registered with ClinicalTrials.gov (NCT00268476) and ISRCTN (ISRCTN78818544).

Findings: Between Nov 15, 2011, and Jan 17, 2014, 1003 patients were randomly assigned to standard of care (n=502) or standard of care plus abiraterone (n=501) in the abiraterone trial. Between July 29, 2014, and March 31, 2016, 916 patients were randomly assigned to standard of care (n=454) or standard of care plus abiraterone and enzalutamide (n=462) in the abiraterone and enzalutamide trial. Median follow-up was 96 months (IQR 86-107) in the abiraterone trial and 72 months (61-74) in the abiraterone and enzalutamide trial. In the abiraterone trial, median overall survival was 76·6 months (95% CI 67·8-86·9) in the abiraterone group versus 45·7 months (41·6-52·0) in the standard of care group (hazard ratio [HR] 0·62 [95% CI 0·53-0·73]; p<0·0001). In the abiraterone and enzalutamide trial, median overall survival was 73·1 months (61·9-81·3) in the abiraterone and enzalutamide group versus 51·8 months (45·3-59·0) in the standard of care group (HR 0·65 [0·55-0·77]; p<0·0001). We found no difference in the treatment effect between these two trials (interaction HR 1·05 [0·83-1·32]; p_interaction=0·71) or between-trial heterogeneity (I² p=0·70). In the first 5 years of treatment, grade 3-5 toxic effects were higher when abiraterone was added to standard of care (271 [54%] of 498 vs 192 [38%] of 502 with standard of care) and the highest toxic effects were seen when abiraterone and enzalutamide were added to standard of care (302 [68%] of 445 vs 204 [45%] of 454 with standard of care). Cardiac causes were the most common cause of death due to adverse events (five [1%] with standard of care plus abiraterone and enzalutamide [two attributed to treatment] and one (<1%) with standard of care in the abiraterone trial).

Interpretation: Enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. Clinically important improvements in survival from addition of abiraterone to androgen deprivation therapy are maintained for longer than 7 years.

Funding: Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests GA reports personal fees, grants, and travel support from Janssen and Astellas; personal fees or travel support from Pfizer, Ipsen, Novartis (Advanced Accelerator Applications), Abbott Laboratories, Ferring, ESSA Pharmaceuticals, Bayer Healthcare Pharmaceuticals, BeiGene, Takeda, AstraZeneca, and Sanofi Aventis; grant support from AstraZeneca, Innocrin Pharma, and Arno Therapeutics; receives a share of the royalty income from The Institute of Cancer Research Rewards to Discoverers Scheme for abiraterone; and holds a patent on plasma methylation signatures as biomarkers for prostate cancer (GB1915469.9). LM, AC, CB, CG, HR, CLA, CM, NP, CP, CD-M, DG, MRS, LCB, REL, and MKBP report research grants for the STAMPEDE trial from Janssen, Astellas, Novartis, Sanofi, and Clovis. NWC reports personal fees from Janssen and Astellas. AS reports grants or contracts with the National Institute for Health Research, John Black Charitable Foundation, and Prostate Cancer Foundation. RJJ reports research grants from Astellas, Clovis, Exelixis, Bayer, and Roche; and advisory board participation and speaker's honoraria from Janssen, Astellas, Bayer, Novartis, Pfizer, Merck Serono, MSD, Roche, Ipsen, and Bristol Myers Squibb. CCP reports consulting fees from Advanced Accelerator Applications, ITM Radiopharma, Myovant, and Clarity Pharmaceuticals; and speaker's honoraria from Janssen and Bayer. SG reports consulting fees from Tolremo; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, educational events, and honoraria from Silvio Grasso Consulting, WebMD (Medscape), European Society of Medical Oncology, Orikata, Swiss Group for Clinical Cancer Research, Beijing United Family Hospital and Clinics, Deutchland European School of Oncology, Swiss Academy of Multidisciplinary Oncology, PeerVoice, and Radiotelevisione Svizzera Italiana; travel support from Proteomedix and AstraZeneca; a patent for biomarker discovery (WO 2009138392 A1); advisory board participation for Janssen, MSD, Bayer, Roche, Astellas, Pfizer, Telixpharma, Bristol Myers Squibb, Advanced Accelerator Applications, Orion, Novartis, Modra Pharmaceuticals, AstraZeneca, Myriad Genetic, and Amgen; and a scientific committee role for Pfizer. CG reports institution funding from Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi Genzyme; and charitable funding from Cancer Research UK and Medical Research Council. SC reports consulting fees from Telix, Novartis (Advanced Accelerator Applications), Huma, Remedy Bio, and Curesponse; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Bayer, Janssen, Astellas, Amgen, and Advanced Accelerator Applications; participation on a data safety monitoring board or advisory board for Amgen, Janssen, and Bayer; and stocks in Huma and Remedy Bio. JMO reports a grant from Prostate Cancer UK. AB reports speaker's fees from Janssen, Astellas, Bristol Myers Squibb, Roche, MSD, and Bayer; support for attending meetings and travel from Janssen and Bayer; and participation on a data safety monitoring board or advisory board for Janssen, Bristol Myers Squibb, and AstraZeneca. NS reports support for travel expenses from Janssen-Cilag. JT reports support from Janssen and Astellas for conference attendance; and participation in advisory boards for Janssen and Astellas. PD reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Pfizer, Bristol Myers Squibb, Ipsen, EUSA Pharma, and EISAI; support for attending meetings or travel from Janssen and Ipsen; and participation on a data safety monitoring board or advisory board for Pfizer and EUSA Pharma. OP reports support for educational meetings and conference attendance from Janssen and Astellas. AR reports sponsorships for attending a conference from Janssen. AHM reports sponsorship to attend an educational meeting from Astellas. RC reports consulting fees from Astellas, Bayer, Novartis, Janssen, Sanofi, Pfizer, MSD, Bristol Myers Squibb, Roche, Debiopharm, AstraZeneca, Ipsen, and Merck; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Astellas, Janssen, Roche, and Merck; and participation as a board member for the Swiss Group for Clinical Cancer Research. DPD reports consulting fees and participation on an advisory board for Janssen; and a patent for a localisation and stabilisation device (EP1933709B1). MRS reports speaker fees from Eisai and being a non-paid member of independent data monitoring committees for academic sponsors. NDJ reports research grants for the STAMPEDE trial from Janssen, Astellas, Novartis, Sanofi, Clovis, and Cancer Research UK; and consulting and lecture fees from Astellas and Janssen. All other authors declare no competing interests.

Figures

**Figure 1. Trial profile**
Patients who did not start research treatment are not included in the safety analysis. All randomly assigned patients are included in the efficacy analyses. Abiraterone refers to abiraterone acetate and prednisolone. *Metastatic status was updated by recruiting sites for 11 patients after random assignment and after first report of the abiraterone trial; status was changed for six patients from non-metastatic to metastatic disease and for five patients from metastatic to non-metastatic disease. †Patients who withdrew and did not have data in the past 2 years; reasons were provided as free text by site and categorised centrally.

**Figure 2. Overall survival analysis**
Shaded regions represent 95% CIs. Survival curves for the abiraterone and enzalutamide trial are capped at 84 months due to shorter follow-up than in the abiraterone trial. Abiraterone refers to abiraterone acetate and prednisolone. Overall survival in the abiraterone trial (A) and the abiraterone and enzalutamide trial (B), split by low-volume metastatic disease (C, D) and high-volume metastatic disease (E, F). Patients with unknown metastatic volume were not included in the subgroup analysis by metastatic volume.

**Figure 3. Overall survival subgroup analysis**
The dashed line indicates overall hazard ratio. Weighting is by sample size. Abiraterone refers to abiraterone acetate and prednisolone. Prespecified stratification factors at the start of accrual in the abiraterone trial with standard of care plus abiraterone treatment (A) and in the abiraterone and enzalutamide trial with standard of care plus abiraterone plus enzalutamide treatment (B) and by planned use of docetaxel, allowed after amendment of the abiraterone and enzalutamide trial (C). Additional prespecified analysis shows low-volume metastatic disease (D) and high-volume metastatic disease (E). NR=not reached.

**Figure 4. Secondary efficacy endpoint analysis**
Shaded regions represent 95% CIs. Survival curves for the abiraterone and enzalutamide trial are capped at 84 months due to shorter follow-up than in the abiraterone trial. Abiraterone refers to abiraterone acetate and prednisolone. Prostate cancer-specific survival (A, B), failure free survival (C, D) and metastatic progression free survival (E, F) in the abiraterone and abiraterone and enzalutamide trials.

See this image and copyright information in PMC

Comment in

Metastatic prostate cancer management: 20 years of progress.
Gravis G. Gravis G. Lancet Oncol. 2023 May;24(5):416-417. doi: 10.1016/S1470-2045(23)00167-5. Lancet Oncol. 2023. PMID: 37142365 No abstract available.

References

1. James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019. Eur Urol. 2015;67:1028–38. - PubMed
1. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46. doi: 10.1056/NEJMoa1503747. - DOI - PMC - PubMed
1. Parmar MK, Sydes MR, Cafferty FH, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols. Clin Trials. 2017;14:451–61. doi: 10.1177/1740774517725697. - DOI - PMC - PubMed
1. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51. doi: 10.1056/NEJMoa1702900. - DOI - PMC - PubMed
1. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77. doi: 10.1016/S0140-6736(15)01037-5. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov
Actions
- Search in PubMed
- Search in ISRCTN Controlled Trials

Grants and funding

MC_UU_12023/25/MRC_/Medical Research Council/United Kingdom

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Collaborators

Affiliations

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

References

Publication types

MeSH terms

Substances

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials